ESMO 2019: Ovarian cancer drug fails to meet primary endpoint in study - 1 views
-
jacob logan on 10 Oct 19ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).